"How should a family office own biotech: directly, or through managers?"

Family offices in biotech do both at once: direct cheques into companies and LP positions in funds doing the same thing. Edge or expensive contradiction? Matthias Voss and Stephan Huber (Navec Investment) open the question: what a family office sees that a manager cannot and the other way round, how you pick a life science fund when DPI is meaningless for a decade, and whether the fund is really about returns or about access and co-investment. Come with a position.

Host:
Stephan Huber (NAVEC)
Matthias Voss (Investor's Kitchen)
‍
What are Roundtables?
Roundtables are curated sessions for 15 selected individuals, led by prominent LPs. The format features a 45-minute peer-level exchange on market realities, governed by the Chatham House Rule. This confidential setting connects you directly with influential allocators, and fosters deep, authentic relationship building through candid discussion.